Search Results - "KURZMAN, Ilene D"

Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting by Magee, Kara, Marsh, Ian R, Turek, Michelle M, Grudzinski, Joseph, Aluicio-Sarduy, Eduardo, Engle, Jonathan W, Kurzman, Ilene D, Zuleger, Cindy L, Oseid, Elizabeth A, Jaskowiak, Christine, Albertini, Mark R, Esbona, Karla, Bednarz, Bryan, Sondel, Paul M, Weichert, Jamey P, Morris, Zachary S, Hernandez, Reinier, Vail, David M

“…Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted…”
Get full text

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor by Grosenbaugh, Deborah A, Leard, A Timothy, Bergman, Philip J, Klein, Mary K, Meleo, Karri, Susaneck, Steven, Hess, Paul R, Jankowski, Monika K, Jones, Pamela D, Leibman, Nicole F, Johnson, Maribeth H, Kurzman, Ilene D, Wolchok, Jedd D

“…To evaluate the safety and efficacy of a vaccine containing plasmid DNA with an insert encoding human tyrosinase (ie, huTyr vaccine) as adjunctive treatment…”
Get full text

Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation by THAMM, Douglas H, KURZMAN, Ilene D, KING, Ivan, ZUJIN LI, SZNOL, Mario, DUBIELZIG, Richard R, VAIL, David M, MACEWEN, E. Gregory

“…Purpose: Genetically modified bacteria are a potentially powerful anticancer therapy due to their tumor targeting capacity, inherent antitumor activity, and…”
Get full text

Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma by VAIL, David M, THAMM, Douglas H, JERAJ, Robert, VANDERHOEK, Matt, PLAZA, Susan, ANDERSON, Christie, WESSEL, Mackenzie A, REBATE, Cecilia, LAWRENCE, Jessica, TUMAS, Daniel B, REISER, Hans, RAY, Adrian S, WOLFGANG, Grushenka H. I, WATKINS, William J, BABUSIS, Darius, HENNE, Ilana N, HAWKINS, Michael J, KURZMAN, Ilene D

“…Purpose: To assess, in dogs with naturally occurring non-Hodgkin's lymphoma, pharmacokinetics, safety, and activity of GS-9219, a prodrug of the nucleotide…”
Get full text

IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma by MacEwen, E. Gregory, Pastor, Josep, Kutzke, Jonathan, Tsan, Rachel, Kurzman, Ilene D., Thamm, Douglas H., Wilson, Mike, Radinsky, Robert

“…To further define the role of insulin‐like growth factor‐1 (IGF‐1) and its receptor (IGF‐1R) in osteosarcoma (OS), human OS cell lines with low (SAOS‐2) and…”
Get full text

Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma by Albertini, Mark R, Zuleger, Cindy L, Ranheim, Erik A, Shiyanbola, Oyewale, Sondel, Paul M, Morris, Zachary S, Eickhoff, Jens, Newton, Michael A, Ong, Irene M, Schwartz, Rene Welch, Hayim, Rubi, Kurzman, Ilene D, Turek, Michelle, Vail, David M

“…Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it…”
Get full text

Liposome-Encapsulated Doxorubicin (Doxil) and Doxorubicin in the Treatment of Vaccine-Associated Sarcoma in Cats by Poirier, Valerie J., Thamm, Douglas H., Kurzman, Ilene D., Jeglum, K. Ann, Chun, Ruthanne, Obradovich, Joyce E., O'Brien, Maura, Fred III, Rogers M., Phillips, Brenda S., Vail, David M.

“…The purpose of this randomized, multicenter study was to evaluate the toxicity and efficacy of liposome‐encapsulated doxorubicin (LED) and doxorubicin (DOX) in…”
Get full text

Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs by Burton, Jenna H, Johnston, Stephen Albert, Vail, David M, Eickhoff, Jens C, Sykes, Kathryn F, Brown, Justin R, Shen, Luhui, Gervassi, Ana, Page, Rodney L, Willcox, Jennifer L, Al-Nadaf, Sami, Willis, Amanda L, Biggs, Danielle, Ralston, Jessica, Mok, Irene, Kurzman, Ilene D, Huelsmeyer, Michael K, Hayim, Rubi, Smith, Brittany M, Thamm, Douglas H

“…Preventative anti-cancer vaccination strategies have long been hampered by the challenge of targeting the diverse array of potential tumor antigens, with…”
Get full text

Cisplatin and Doxorubicin Combination Chemotherapy for the Treatment of Canine Osteosarcoma: A Pilot Study by Chun, Ruthanne, Kurzman, Ilene D., Couto, C. Guillermo, Klausner, Jeff, Henry, Carolyn, MacEwen, E. Gregory

“…Sixteen dogs with histologically confirmed appendicular osteosarcoma were treated by amputation followed by cisplatin and doxorubicin chemotherapy. All dogs…”
Get full text

Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery by Ma, Yonghui, Manolache, Sorin, Denes, Ferencz S., Thamm, Douglas H., Kurzman, Ilene D., Vail, David M.

“…Using dense medium plasma technology, carbon magnetic nanoparticles (CMNP) were synthesized at room temperature and atmospheric pressure. Based on results from…”
Get full text

Clinical signs, treatments, and outcome in cats with transitional cell carcinoma of the urinary bladder: 20 cases (1990-2004) by Wilson, Heather M, Chun, Ruthanne, Larson, Victoria S, Kurzman, Ilene D, Vail, David M

“…To characterize demographics and clinical signs and evaluate outcomes of treatments in cats with transitional cell carcinoma (TCC) of the urinary bladder…”
Get full text

Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase I Evaluation by THAMM, Douglas H, KURZMAN, Ilene D, CLARK, Mike A, EHRHART, E. J, KRAFT, Susan L, GUSTAFSON, Daniel L, VAIL, David M

“…Tumor necrosis factor-alpha (TNF) is a cytokine with potent antitumor activity; however, toxicity and short half-life have limited its utility. Polyethylene…”
Get full text

GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma by Thamm, Douglas H, Vail, David M, Kurzman, Ilene D, Babusis, Darius, Ray, Adrian S, Sousa-Powers, Noel, Tumas, Daniel B

“…Multiple myeloma (MM) is an important human and canine cancer for which novel therapies remain necessary. VDC-1101 (formerly GS-9219), a novel double prodrug…”
Get full text

Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma by Zuleger, Cindy L., Kang, Chulhi, Ranheim, Erik A., Kurzman, Ilene D., Macklin, Michael D., Newton, Michael A., Wolchok, Jedd D., Vail, David M., Eriksson, Elof, Albertini, Mark R.

“…Spontaneous canine malignant melanoma provides an excellent pre‐clinical model to study DNA vaccines for melanoma immunotherapy. A USDA‐approved xenogeneic…”
Get full text

GS-9219/VDC-1101 - a prodrug of the acyclic nucleotide PMEG has antitumor activity inspontaneous canine multiple myeloma by Thamm, Douglas H, Vail, David M, Kurzman, Ilene D, Babusis, Darius, Ray, Adrian S, Sousa-Powers, Noel, Tumas, Daniel B

“…Background Multiple myeloma (MM) is an important human and canine cancer for which novel therapies remain necessary. VDC-1101 (formerly GS-9219), a novel…”
Get full text

RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target by Thamm, Douglas H, Huelsmeyer, Michael K, Mitzey, Ann M, Qurollo, Barbara, Rose, Barbara J, Kurzman, Ilene D

“…Canine malignant melanoma (CMM) resembles human malignant melanoma in terms of metastatic behavior, refractoriness to standard therapy, and tumor antigen…”
Get full text

Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma by KATAYAMA, Rieko, HUELSMEYER, Michael K, MARR, Amanda K, KURZMAN, Ilene D, THAMM, Douglas H, VAIL, David M

“…Feline vaccine-associated sarcoma (VAS) is a biologically aggressive soft-tissue sarcoma that can develop at sites where inactivated feline vaccines have been…”
Get full text

Adjuvant Therapy for Melanoma in Dogs: Results of Randomized Clinical Trials Using Surgery, Liposome-encapsulated Muramyl Tripeptide, and Granulocyte Macrophage Colony-stimulating Factor by MACEWEN, E. G, KURZMAN, I. D, ROSENTHAL, R. C, FOX, L. E, ROSENBERG, M, HENRY, C, FIDEL, J, VAIL, D. M, DUBIELZIG, R. R, EVERLITH, K, MADEWELL, B. R, RODRIGUEZ, C. O, PHILLIPS, B, ZWAHLEN, C. H, OBRADOVICH, J

“…Spontaneous canine oral melanoma (COM) is a highly metastatic cancer, resistant to chemotherapy, and can serve as a model for cancer immunotherapy…”
Get full text

Inhalation Chemotherapy for Macroscopic Primary or Metastatic Lung Tumors: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model by HERSHEY, A. E, KURZMAN, I. D, FORREST, L. J, BOHLING, C. A, STONEROOK, M, PLACKE, M. E, IMONDI, A. R, VAIL, D. M

“…This study represents part of an effort to determine the safety and efficacy of inhaled antineoplastic drugs, using pet dogs with spontaneously arising primary…”
Get full text

STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial by VAIL, David M, KURZMAN, Ilene D, WORKING, Peter K, GLAWE, Phyllis C, O'BRIEN, Maura G, CHUN, Ruthanne, GARRETT, Laura D, OBRADOVICH, Joyce E, FRED, Rogers M, KHANNA, Chand, COLBERN, Gail T

“…This trial was designed to compare the efficacy of adjuvant STEALH liposome-encapsulated cisplatin (SPI-77) to "standard-of-care" carboplatin therapy in dogs…”
Get full text